A Single-Arm, Low-Dose, Prospective Study of<sup>177</sup>Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Single-Arm, Low-Dose, Prospective Study of¹⁷⁷Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Published:2022-11-03 Issue:4 Volume:64 Page:611-617
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Wang Guochang,Zang Jie,Jiang Yuanyuan,Liu Qingxing,Sui Huimin,Wang Rongxi,Fan Xinrong,Zhang Jingjing,Zhu Zhaohui,Chen Xiaoyuan

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference35 articles.

1. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet.,2021

3. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial;Satapathy;Eur J Nucl Med Mol Imaging.,2022

4. Roche’s anti-TIGIT drug suffers a phase III cancer setback

5. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer;European Urology Focus;2024-08

2. FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model;Journal of Medicinal Chemistry;2024-07-16

3. Landscape of Nuclear Medicine in China and Its Progress on Theranostics;Journal of Nuclear Medicine;2024-05

4. From biology to the clinic — exploring liver metastasis in prostate cancer;Nature Reviews Urology;2024-04-26

5. Progress and application of intelligent nanomedicine in urinary system tumors;Journal of Pharmaceutical Analysis;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3